Clareo Health | Combination of Equisetum Arvense and Palmitoylethanolamide (PEA) for the Management of Patients With Chronic Pain in a Before-after Study
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
noiVita Srls
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients between 18 and 80 years of age.
Pain beyond 3 months, even intermittent, timing is necessary to have a pattern of chronic pain.
Signature of informed consent.
Paracetamol use in the last 3 months.
You may not be if
Drug treatment for chronic pain (e.g., acetyl-L-carnitine, tricyclic antidepressants, opioids, antiepileptics) would lead to incorrect interpretation of data.
Pharmacological treatment for arthritis pain would lead to an incorrect interpretation of the data.
Psychiatric disorders or cognitive dysfunction in patients with these disorders could result in the completion of questionnaires that are not useful for the final assessment.
Concomitant severe brain damage.
Tumours or terminal illnesses.
Pregnancy or lactation.
Alcohol or substance abuse.
Allergies or intolerance to the product as it would cause serious adverse side effects
